(225)Ac-PSMA-617 in chemotherapy-naive patients with advanced prostate cancer: a pilot study

BACKGROUND: A remarkable therapeutic efficacy has been demonstrated with (225)Ac-prostate-specific membrane antigen (PSMA)-617 in heavily pre-treated metastatic castration-resistant prostate cancer (mCRPC) patients. We report our experience with (225)Ac-PSMA-617 therapy in chemotherapy-naïve patient...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Eur J Nucl Med Mol Imaging
Autors principals: Sathekge, Mike, Bruchertseifer, Frank, Knoesen, Otto, Reyneke, Florette, Lawal, Ismaheel, Lengana, Thabo, Davis, Cindy, Mahapane, Johncy, Corbett, Ceceila, Vorster, Mariza, Morgenstern, Alfred
Format: Artigo
Idioma:Inglês
Publicat: Springer Berlin Heidelberg 2018
Matèries:
Original Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6267694/
https://ncbi.nlm.nih.gov/pubmed/30232539
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00259-018-4167-0
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars